Related Experiment Video
Updated: Dec 4, 2025
Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
Published on: May 2, 2013
Serum Amyloid A in lung transplantation
Lucia Vietri1, Elena Bargagli1, David Bennett1
1Department of Medical and Surgical Sciences and Neurosciences, Respiratory Disease and Lung Transplant Unit, University of Siena, AOUS, Siena, Italy.
Serum Amyloid A (SAA) may indicate lung transplant complications. Elevated SAA levels were observed in lung transplant recipients, especially those with acute rejection or infection, suggesting its potential as a biomarker.
Area of Science:
- Immunology
- Pulmonology
- Biomarker Discovery
Background:
- Serum Amyloid A (SAA) is an acute-phase protein.
- Analysis of SAA concentrations in lung transplant recipients (LTX) was conducted.
Purpose of the Study:
- To investigate SAA levels in LTX patients.
- To evaluate SAA as a potential biomarker for LTX complications.
Main Methods:
- Studied 26 LTX patients and 11 healthy controls.
- Classified LTX patients into groups: acute rejection (AR), bronchiolitis obliterans syndrome (BOS), infection (INF), and stable (NEG).
Main Results:
- LTX patients showed significantly increased SAA concentrations compared to controls.
- Elevated SAA levels were particularly noted in AR and INF groups.
- In LTX-AR patients, SAA correlated positively with CD4+ lymphocyte percentage and negatively with FVC percentage.
Conclusions:
- SAA may serve as a potential biomarker for acute complications following lung transplantation.
- SAA demonstrates prognostic value in cases of acute rejection after LTX.
More Related Videos
06:15Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation
Published on: November 10, 2023
04:42Author Spotlight: Analyzing Fibrosis Development in Chronic Lung Allograft Rejection Using Picrosirius Red Staining in Mouse Models
Published on: March 21, 2025